ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Size: px
Start display at page:

Download "ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes"

Transcription

1 ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Effects of a fixed combination of the ACE inhibitor, perindopril, and the diuretic, indapamide on major vascular events

2 Blood pressure and vascular risk in diabetes Best evidence: 2000 UK Prospective Diabetes Study

3 Blood pressure and vascular risk in diabetes Best evidence: 2000 UKPDS SBP UK Prospective Diabetes Study

4 Blood pressure lowering in diabetes: Unresolved issues 2000 Among patients with diabetes, does blood pressure lowering therapy: Produce additional benefits when systolic pressure is lowered below 145 mmhg? Produce similar benefits for hypertensive and non-hypertensive patients? Add to the benefits produced by other cardiovascular preventive therapies including ACE inhibitors?

5 ADVANCE study hypotheses Perindopril-indapamide arm Among patients with diabetes, does blood pressure lowering therapy: Produce additional benefits when systolic pressure is lowered below 145 mmhg? Produce similar benefits for hypertensive and non-hypertensive patients? Add to the benefits produced by other cardiovascular preventive therapies including ACE inhibitors?

6 Inclusion criteria Type 2 diabetes mellitus Age 55 years or older Additional risk of vascular event Age 65 years History of major macrovascular disease History of major microvascular disease First diagnosis of diabetes >10 years prior to entry Other major risk factor Hypertensive or normotensive

7 Randomised study treatments Blood pressure lowering Double-blind perindopril-indapamide versus matching placebo 2.0 / 0.625mg or placebo for first 3 months 4.0 / 1.25mg or placebo thereafter Blood glucose lowering (ongoing) Open-label gliclazide MR-based intensive therapy targeting an HbA1c of 6.5% versus usual guideline-based care

8 Randomised study treatments Blood pressure lowering Double-blind perindopril-indapamide versus matching placebo 2.0 / 0.625mg or placebo for first 3 months 4.0 / 1.25mg or placebo thereafter Blood glucose lowering (ongoing) Open-label gliclazide MR-based intensive therapy targeting an HbA1c of 6.5% versus usual guideline-based care

9 Ancillary drug treatment Blood pressure lowering therapy At discretion of treating physician Only thiazide diuretic contraindicated ACE inhibitor Open-label perindopril (up to 4 mg daily), if indicated All other treatment At discretion of treating physician Except glucose control for those assigned intensive therapy

10 Primary study outcomes Macrovascular Non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause (including sudden death) Microvascular New of worsening nephropathy or diabetic eye disease Prespecified analyses: Macrovascular and microvascular jointly Macrovascular and microvascular separately

11 ADVANCE Trial profile with type 2 diabetes registered 1737 withdrew during run-in randomised 5569 assigned perindoprilindapamide combination 4 lost to follow-up 5571 assigned matching placebo 11 lost to follow-up Scheduled end of follow-up: 4.3 years 4908 (88%) assessed at final visit 4081 (73%) adherent to treatment Scheduled end of follow-up: 4.3 years 4863 (87%) assessed at final visit 4143 (74%) adherent to treatment

12 Baseline characteristics Randomised treatment Age (years) Systolic blood pressure (mmhg) Diastolic blood pressure (mmhg) Haemoglobin A1c (%) History of macrovascular disease History of microvascular disease Microalbuminuria Active (n=5569) % 10% 26% Placebo (n=5571) % 10% 26%

13 Baseline characteristics Cardiovascular and diabetes drugs Any blood pressure lowering drug ACE inhibitor* Oral hypoglycaemic drugs Statin Other lipid modifying drug Aspirin Other antiplatelet drugs Randomised treatment Active (n=5569) 75% 43% 91% 28% 9% 44% 4% Placebo (n=5571) 75% 43% 91% 29% 8% 44% 5% *By end of run-in period: 47% were receiving open label perindopril

14 Main results Blood pressure

15 Blood pressure reduction Mean Blood Pressure (mmhg) Placebo Perindopril-Indapamide Δ 5.6 mmhg (95% CI ); p<0.001 Δ 2.2 mmhg (95% CI ); p<0.001 Follow-up (Months) Systolic Diastolic R Average BP during follow-up mmhg mmhg 77.0 mmhg 74.8 mmhg

16 ADVANCE BP reduction in context: UK Prospective Diabetes Study ADV UKPDS SBP UK Prospective Diabetes Study

17 Main results Mortality and morbidity

18 All-cause mortality 10 Placebo Perindopril-Indapamide Cumulative incidence (%) 5 Relative risk reduction 14%: 95% CI 2-25% p= Follow-up (months)

19 Deaths Cumulative incidence (%) Cardiovascular 5% Placebo 5% Perindopril-indapamide Relative risk reduction 18%; p= Follow-up (months) Non-cardiovascular Placebo Perindopril-indapamide Relative risk reduction 8%; p= Follow-up (months)

20 Combined primary outcomes Major macro or microvascular event 20 Placebo Perindopril-Indapamide Cumulative incidence (%) 10 Relative risk reduction 9%: 95% CI: 0 to 17% p= Follow-up (months)

21 Primary outcomes Major macro or microvascular event Number of events Per-Ind Placebo (n=5,569) (n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) Combined macro+micro % (0 to 17) * Macrovascular % (-4 to 19) Microvascular % (-4 to 20) Hazard ratio *2P=0.04

22 Effects by age, sex, BP and HbA1c Combined primary endpoint Number of events Per-Ind Placebo (n=5,569) (n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) Age (years) < % (-10 to 19) >= % (0 to 21) Sex Male % (-1 to 20) Female % (-7 to 21) SBP (mmhg) < % (-5 to 23) % (-2 to 19) History of hypertension No % (-17 to 29) Yes % (0 to 18) HbA1c (%) % (-4 to 20) > % (-1 to 22) All participants % (0 to 17) Hazard ratio 2.0 Phomogeneity all >0.1

23 Effects by ancillary treatment Combined primary endpoint Number of events Per-Ind Placebo (n=5,569)(n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) Treatment with any BP lowering drug No % (-15 to 24) Yes % (0 to 19) Treatment with ACE inhibitor No % (-3 to 21) Yes % (-4 to 20) Treatment with statins No % (0 to 19) Yes % (-10 to 23) Treatment with anti-platelet drug No % (-2 to 22) Yes % (-5 to 18) All participants % (0 to 17) Hazard ratio 2.0 Phomogeneity all >0.1

24 Coronary events Number of events Per-Ind Placebo (n=5,569) (n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) All coronary heart disease % (2 to 24) * Major coronary heart disease % (-6 to 24) Other coronary heart disease % (-1 to 27) Hazard ratio Non-fatal MI or death from coronary heart disease Unstable angina requiring hospitalisation, coronary revascularisation or silent MI *2P=0.02

25 Cerebrovascular events Number of events Per-Ind Placebo (n=5,569) (n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) All cerebrovascular disease % (-10 to 20) * Major cerebrovascular disease % (-18 to 19) Other cerebrovascular disease % (-6 to 41) Hazard ratio Non-fatal stroke or death from cerebrovascular disease Transient ischaemic attack or subarachnoid haemorrhage 2.0 *2P=0.40

26 Renal events Number of events Per-Ind Placebo (n=5,569)(n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) Total renal events % (15 to 27)* New or worsening nephropathy % (-1 to 32) New microalbuminuria % (14 to 27) Hazard ratio 2.0 *2P=<0.01

27 Eye events Number of events Per-Ind Placebo (n=5,569) (n=5,571) Favours Per-Ind Favours Placebo Relative risk reduction (95% CI) Total eye events % (-1 to 10)* New or worsening eye disease % (-18 to 15) Visual deterioration % (-1 to 10) Hazard ratio 2.0 *2P=0.09

28 Absolute benefits of routine treatment with perindopril and indapamide After 5 years, treatment would prevent: One major vascular event One death One coronary event One renal event* Among every 66 patients 79 patients 75 patients 20 patients *mostly new onset microalbuminuria

29 Risk factors levels At end of follow-up Parameter Systolic BP (mmhg) Diastolic BP (mmhg) Haemoglobin A1c (%) Total cholesterol (mmol/l) * HDL cholesterol (mmol/l) * LDL cholesterol (mmol/l) * Triglycerides (mmol/l) * Randomised treatment Active (n=5569) Placebo (n=5571) * Measurements taken at month 48

30 Ancillary drug therapy At end of follow-up Any BP lowering drug ACE inhibitor Oral hypoglycaemic drugs Insulin Statin Other lipid modifying drug Aspirin Other antiplatelet drugs Randomised treatment Active (n=5569) 74% 50% 90% 33% 44% 8% 56% 6% Placebo (n=5571) 83% 60% 91% 30% 45% 7% 55% 6%

31 Summary Routine treatment of type 2 diabetic patients with perindopril-indapamide resulted in: > 14% reduction in total mortality > 18% reduction in cardiovascular death > 9% reduction in major vascular events > 14% reduction in total coronary events > 21% reduction in total renal events Benefits appeared to be similar in all major subgroups. Treatment was very well tolerated, with few side effects and adherence similar to that with placebo.

32 Blood pressure lowering in diabetes: Unresolved issues 2000 Among patients with diabetes, does blood pressure lowering therapy: Produce additional benefits when systolic pressure is lowered below 145 mmhg? YES Produce similar benefits for hypertensive and non-hypertensive patients? YES Add to the benefits produced by other cardiovascular preventive therapies including ACE inhibitors? YES

33 Global projections for diabetes (millions) % % % % % % % World 2007 = 246 million 2025 = 380 million Increase +55% Diabetes Atlas, 3rd edition, IDF 2006

34 Potential global benefits of treatment If the benefits observed in ADVANCE were applied to just half the world s diabetic population Approximately 1.5 million deaths could be avoided over this period Diabetes Atlas, 3rd edition, IDF 2006

35

Type 2 diabetes is a cardiovascular equivalent and should be treated aggressively!

Type 2 diabetes is a cardiovascular equivalent and should be treated aggressively! Type 2 diabetes is a cardiovascular equivalent and should be treated aggressively! Schramm TK et al, 2008 Circulation 117:1945, 2008 Steno-2: Major papers Lancet 1999; 353: 617-22 New Engl J Med 2003;

More information

Rationale for ADA Treatment Guidelines for CVD Prevention. Robert E. Ratner, MD American Diabetes Association

Rationale for ADA Treatment Guidelines for CVD Prevention. Robert E. Ratner, MD American Diabetes Association Rationale for ADA Treatment Guidelines for CVD Prevention Robert E. Ratner, MD American Diabetes Association 1 No Financial Disclosures 2 Trends in age-standardized rates of diabetes-related complications

More information

Diabetes and Hyperlipidemia

Diabetes and Hyperlipidemia Diabetes and Hyperlipidemia State of the art 2010 Lars Rydén Karolinska Institutet Stockholm, Sweden Diabetes and hyperlipidemia Diabetes and hyperlipidemia Treatment targets Treatment targets Lipid category

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE 1 NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Guideline title SCOPE Hypertension: clinical management of primary hypertension in adults 1.1 Short title Hypertension (partial update) 2 The remit

More information

Guidelines for the management of hypertension in patients with diabetes mellitus

Guidelines for the management of hypertension in patients with diabetes mellitus Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes

More information

Impact of Recent Clinical Trials on the Management of Cardiovascular Disease in Diabetes;

Impact of Recent Clinical Trials on the Management of Cardiovascular Disease in Diabetes; 36 th Autumn Congress of Korean Diabetes Association 2010 Impact of Recent Clinical Trials on the Management of Cardiovascular Disease in Diabetes; Blood Pressure control Kim Sin Gon. MD, PhD Associate

More information

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University

More information

Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes

Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes Cardiovascular Outcomes With Alogliptin in Patients With Type 2 Diabetes Mellitus and Recent Acute Coronary Syndromes William B. White, MD for the EXAMINE Investigators Cardiology Center, University of

More information

Cholesterol Treatment Trialists (CTT) Collaboration. Slide deck

Cholesterol Treatment Trialists (CTT) Collaboration. Slide deck Cholesterol Treatment Trialists (CTT) Collaboration Slide deck CTT Collaboration: Background* History: Founded in 1993 (prior to publication of 4S trial in 1994) Original protocol published in 1995 Trial

More information

THE ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR RISK

THE ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR RISK BEST PRACTICE EV I DENCE-BASED GUIDE LINE THE ASSESSMENT AND MANMENT OF CARDIOVASCULAR RISK KEY MESSS Assessment of absolute is the starting point for all discussions with people who have factors measured.

More information

Diabetes Workshop. Type 1 Diabetic. In 2003 at age 42

Diabetes Workshop. Type 1 Diabetic. In 2003 at age 42 Diabetes Workshop September 30, 2014 Mark Schutta, M.D. G. Clayton Kyle Associate Professor of Diabetes Medical Director Penn Rodebaugh Diabetes Center Division of Endocrinology, Diabetes and Metabolism

More information

Cardiovascular Risk Factor Management (Primary Prevention)

Cardiovascular Risk Factor Management (Primary Prevention) Cardiovascular Risk Factor Management (Primary Prevention) Aim(s) and objective(s) Morbidity and mortality from cardiovascular disease (coronary artery disease, cerebrovascular disease and peripheral vascular

More information

Potential Mechanisms of Cardiovascular Benefit for Empagliflozin

Potential Mechanisms of Cardiovascular Benefit for Empagliflozin Potential Mechanisms of Cardiovascular Benefit for Empagliflozin Steven E. Nissen MD MACC Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies

More information

Cardiovascular Disease in Diabetes

Cardiovascular Disease in Diabetes Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality

More information

Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients

Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients European Heart Journal (2000) 21, 2 7 Article No. euhj.1999.1833, available online at http://www.idealibrary.com on Hotline Editorial Dihydropyridine calcium-channel blockers for the treatment of hypertensive

More information

SLOWING DISEASE PROGRESSION IN TYPE 2 DIABETES: LATEST ADVANCES. DR. C.F. OTIENO Dept. of medicine, U.O.N

SLOWING DISEASE PROGRESSION IN TYPE 2 DIABETES: LATEST ADVANCES. DR. C.F. OTIENO Dept. of medicine, U.O.N SLOWING DISEASE PROGRESSION IN TYPE 2 DIABETES: LATEST ADVANCES DR. C.F. OTIENO Dept. of medicine, U.O.N UKPDS: progressive hyperglycemia on monotherapy in type 2 diabetes HbA 1c (%) 10 9 8 Conventional

More information

Understanding diabetes Do the recent trials help?

Understanding diabetes Do the recent trials help? Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.

More information

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Aims: To explore the nature and predictors of amputations in the FIELD Trial Methods: All on study non-traumatic amputations were reviewed in a blinded fashion by two clinicians. Amputations were classified

More information

Quality and Outcomes Framework Programme. NICE cost impact statement

Quality and Outcomes Framework Programme. NICE cost impact statement Quality and Outcomes Framework Programme NICE cost impact statement July 2011 Indicator area: Peripheral arterial disease Indicators NM32 The practice can produce a register of people with peripheral arterial

More information

Does Diabetes Control Matter?

Does Diabetes Control Matter? Does Diabetes Control Matter? Laurence Kennedy, MD, FRCP Endocrinology Department Cleveland Clinic, OH Disclosures None Does Diabetes Control Matter? Generality of patients Relative Risk Complications

More information

Evidence table What is the safety and efficacy of measures to manipulate blood pressure versus treatment as usual in patients with acute stroke?

Evidence table What is the safety and efficacy of measures to manipulate blood pressure versus treatment as usual in patients with acute stroke? 9.3 Blood pressure control Reference Evidence table What is the safety and efficacy of measures to manipulate blood pressure versus treatment as usual in patients with acute? Bath PMW, Willmot M, Leonardi-Bee

More information

Hypertension Guidelines 2016

Hypertension Guidelines 2016 Hypertension Guidelines 6 Michael A. Weber, MD Division of Cardiovascular Medicine State University of New York Downstate Medical Center Speaker Disclosures I disclose that I am a Consultant for: Ablative

More information

Diabetic Nephropathy. Andreas Jehle Transplantation Immunology & Nephrology, University Hospital, Basel

Diabetic Nephropathy. Andreas Jehle Transplantation Immunology & Nephrology, University Hospital, Basel Diabetic Nephropathy Andreas Jehle Transplantation Immunology & Nephrology, University Hospital, Basel Prevalence of ESRD According to Diagnosis (USA) Obesity, D.m. Expectancy of Live USRDS 2013 Incidence

More information

High Blood Pressure in Context. Dr Yassir Javaid GP Northampton Primary Care CVD lead EMSCN

High Blood Pressure in Context. Dr Yassir Javaid GP Northampton Primary Care CVD lead EMSCN High Blood Pressure in Context Dr Yassir Javaid GP Northampton Primary Care CVD lead EMSCN Premature Deaths by Cause in UK, 2012 Men Women Cardiovascular Disease Statistics, 2014 British Heart Foundation

More information

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins

Trends in Prescribing of Drugs for Type 2 Diabetes in General Practice in England (Chart 1) Other intermediate and long-acting insulins Type 2 Diabetes Type 2 diabetes is the most common form of diabetes, accounting for 90 95% of cases. 1 Charts 1 and 2 reflect the effect of increasing prevalence on prescribing and costs of products used

More information

2013 Physician Quality Reporting System Data Collection Form: Hypertension Measures Group (for patients age 18-90)

2013 Physician Quality Reporting System Data Collection Form: Hypertension Measures Group (for patients age 18-90) 2013 Physician Quality Reporting System Data Collection Form: Hypertension Measures Group (for patients age 18-90) Physician Name: Patient Name: Last First MI Gender: Patient Insured - M F Traditional

More information

2014 Physician Quality Reporting System Data Collection Form: Hypertension (for patients aged 18 through 90)

2014 Physician Quality Reporting System Data Collection Form: Hypertension (for patients aged 18 through 90) 2014 Physician Quality Reporting System Data Collection Form: Hypertension (for patients aged 18 through 90) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy Gender: M F Patient

More information

SPRINT: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL

SPRINT: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL 1 SPRINT: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD-PRESSURE CONTROL Presenter: Mackenzie Clark, PharmD, BCPS University of California, San Francisco Medical Center 2 Disclosures I have no

More information

Aspirin in CKD and in Diabetes

Aspirin in CKD and in Diabetes Aspirin in CKD and in Diabetes Alberto Zanchetti, Centro di Fisiologia Clinica e Ipertensione, Università di Milano Istituto Auxologico Italiano, Milano (Italia) Questions 1. Does aspirin reduce CVD outcomes

More information

Quiz 1 hypertension answers. The correct answers to questions are indicated by *.

Quiz 1 hypertension answers. The correct answers to questions are indicated by *. 1 Quiz 1 hypertension answers The correct answers to questions are indicated by *. All students were awarded 2 points for question #3 due answer b being misleading. The answer should have read b. calcium

More information

Lipid Management in CKD: Insights from the SHARP Trial

Lipid Management in CKD: Insights from the SHARP Trial 1 Lipid Management in CKD: Insights from the SHARP Trial George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Center The University of Chicago-Pritzker School of Medicine

More information

Hypertension Clinical Practice Guidelines

Hypertension Clinical Practice Guidelines NATIONAL CLINICAL PRACTICE GUIDELINES Hypertension Clinical Practice Guidelines These guidelines are informational only. They are not intended or designed as a substitute for the reasonable exercise of

More information

6.3 Ischaemic heart disease

6.3 Ischaemic heart disease 6.3 Ischaemic heart disease See Background Paper 6.3 (BP6_3IHD.pdf) Introduction This chapter addresses cardiovascular disease (CVD) with a focus on the development, justification and evidence for the

More information

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results Paul K. Whelton, MB, MD, MSc Chair, SPRINT Steering Committee Tulane University School of Public Health and Tropical Medicine, and

More information

Blood Pressure: Thresholds and Treatment

Blood Pressure: Thresholds and Treatment Blood Pressure: Thresholds and Treatment Professor Neil Poulter ICCH, Imperial College London, UK BHS Primary Care Meeting, London May 17 2011 Management of hypertension: the issues Measurement Classification

More information

What is meant by "randomization"? (Select the one best answer.)

What is meant by randomization? (Select the one best answer.) Preview: Post-class quiz 5 - Clinical Trials Question 1 What is meant by "randomization"? (Select the one best answer.) Question 2 A. Selection of subjects at random. B. Randomization is a method of allocating

More information

Cardiovascular Risk in Diabetes

Cardiovascular Risk in Diabetes Cardiovascular Risk in Diabetes Lipids Hypercholesterolaemia is an important reversible risk factor for cardiovascular disease and should be tackled aggressively in all diabetic patients. In Type 1 patients,

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Impact of Sitagliptin on Heart Failure and Related Outcomes

Impact of Sitagliptin on Heart Failure and Related Outcomes Impact of Sitagliptin on Heart Failure and Related Outcomes Paul W. Armstrong MD University of Alberta Frans Van de Werf, MD, PhD University of Leuven, Belgium 2 Paul W Armstrong Disclosures Research grants

More information

2014 Physician Quality Reporting System Data Collection Form: Cardiovascular Prevention (for patients aged 18 and older)

2014 Physician Quality Reporting System Data Collection Form: Cardiovascular Prevention (for patients aged 18 and older) 2014 Physician Quality Reporting System Data Collection Form: Cardiovascular Prevention (for patients aged 18 and older) Physician Name: Patient Name: Last First MI Date of Birth: / / mm dd yyyy Gender:

More information

Guideline for the diagnosis and management of hypertension in adults National Heart Foundation of Australia

Guideline for the diagnosis and management of hypertension in adults National Heart Foundation of Australia Guideline for the diagnosis and management of hypertension in adults - 2016 2016 National Heart Foundation of Australia Guideline Aim To provide health professionals with the latest evidence for controlling

More information

Yes, it does, but should it?

Yes, it does, but should it? Does Gender Make a Difference When Managing CVD in General Practice? Does Gender Make a difference in the Treatment of CHD? Dr Jennifer Johns MBBS, FRACP, FCSANZ Cardiologist Austin Health Cardiologist

More information

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary

UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS. - Summary UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA DOCTORAL SCHOOL DOCTORATE THESIS - Summary CHRONIC COMPLICATIONS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS - Epidemiological study - PhD Manager: Professor PhD.

More information

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. Kidney Complications Diabetic Nephropathy Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria. The peak incidence of nephropathy is usually 15-25 years

More information

Cardiovascular risk management: Current controversies

Cardiovascular risk management: Current controversies Cardiovascular risk management: Current controversies Medwise March 2014 Clinical Controversy Middle English controversie, from Anglo-French, from Latin controversia, from controversus strong disagreement

More information

Hypertension: How New Guidelines Should Change Your Practice? Overview of Presentation

Hypertension: How New Guidelines Should Change Your Practice? Overview of Presentation Hypertension: How New Guidelines Should Change Your Practice? Kenneth A. Jamerson, MD Professor of Internal Medicine Frederick G. L. Huetwell Collegiate Professor of Cardiovascular Medicine University

More information

A Retrospective Cohort Study of All-Cause Mortality and. Cardiovascular Disease in Thailand

A Retrospective Cohort Study of All-Cause Mortality and. Cardiovascular Disease in Thailand A Retrospective Cohort Study of All-Cause Mortality and Cardiovascular Events In Patients with Established Cardiovascular Disease in Thailand Tarinee Tangcharoen, MD. Division of Cardiology, Department

More information

Diabetes Complications

Diabetes Complications Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation

More information

Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia Guidelines

Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia Guidelines College of Pharmacy and Nutrition University of Saskatchewan Saskatoon SK S7N 5C9 www.medsask.usask.ca Vol. 31, No. 2 April 2014 Watch for Potential Changes in Canada s Current Hypertension and Dyslipidemia

More information

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide

More information

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,

More information

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic

More information

South African Cholesterol Guidelines Compared

South African Cholesterol Guidelines Compared South African Cholesterol Guidelines Compared Jacqueline van Schoor, Amayeza Info Centre While infectious diseases are currently the leading cause of death in South Africa, cardiovascular disease (CVD)

More information

Cardiovascular Combination Pharmacotherapy Global Summit, 2014 from concept to reality

Cardiovascular Combination Pharmacotherapy Global Summit, 2014 from concept to reality Cardiovascular Combination Pharmacotherapy Global Summit, 2014 from concept to reality Major Trials in Progress HOPE 3, HOPE 4, TIPS 3 Koon K. Teo, MB, PhD, McMaster University Melbourne May 8 th, 2014

More information

DGAFMS MEDICAL MEMORANDUM No 151 ESSENTIAL HYPERTENSION. Introduction

DGAFMS MEDICAL MEMORANDUM No 151 ESSENTIAL HYPERTENSION. Introduction DGAFMS MEDICAL MEMORANDUM No 151 ESSENTIAL HYPERTENSION Introduction 1. Hypertension is a common cause of morbidity & occasional mortality among Armed Forces personnel. Untreated or inadequately treated

More information

SYNOPSIS. Abbreviated Clinical Study Report CV Abbreviated Clinical Study Report

SYNOPSIS. Abbreviated Clinical Study Report CV Abbreviated Clinical Study Report SYNOPSIS TITLE OF STUDY: PRAVASTATIN OR ATORVASTATIN EVALUATION AND INFECTION THERAPY - PROVE IT - (TIMI22) INVESTIGATORS: Eugene Braunwald, MD (Chairman), Christopher Cannon, MD (Principal Investigator);

More information

AHA/ASA Guidelines on Prevention of Recurrent Stroke

AHA/ASA Guidelines on Prevention of Recurrent Stroke AHA/ASA Guidelines on Prevention of Recurrent Stroke MARA LAMBERT Guideline source: American Heart Association/American Stroke Association Evidence rating system used? Yes Literature search described?

More information

SWEDISH NATIONAL DIABETES REGISTER

SWEDISH NATIONAL DIABETES REGISTER SWEDISH NATIONAL DIABETES REGISTER The Swedish National Diabetes Register To improve diabetes care Started 1996 Internet-based quality registry Interactive statistical reports Immediate access real-time

More information

Prevention of Cardiovascular Disease in Children with Diabetes

Prevention of Cardiovascular Disease in Children with Diabetes Prevention of Cardiovascular Disease in Children with Diabetes Stephen R. Daniels, MD, PhD Department of Pediatrics University of Colorado School of Medicine The Children s Hospital Anschutz Medical Campus

More information

Main Effect of Screening for Coronary Artery Disease Using CT

Main Effect of Screening for Coronary Artery Disease Using CT Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,

More information

The HOPE Study and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus

The HOPE Study and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus The HOPE Study and MICRO-HOPE Substudy: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus VINOD PATEL, 1 SRINIVAS PANJA, 1 ASOK VENKATARAMAN 2 Background

More information

Statins and Risk for Diabetes Mellitus. Background

Statins and Risk for Diabetes Mellitus. Background Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration

More information

Thank you for joining The Guideline Advantage this afternoon! To access the audio portion: Dial: (866) Conference ID:

Thank you for joining The Guideline Advantage this afternoon! To access the audio portion: Dial: (866) Conference ID: Thank you for joining The Guideline Advantage this afternoon! To access the audio portion: Dial: (866) 832-6378 Conference ID: 91889463 We will be starting the presentation shortly. 1 Vision & Goal Vision

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 25 September 2008 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE

More information

We used propensity score matching (PPM) to identify patients treated with statins prior to stroke and matched untreated patients to limit the

We used propensity score matching (PPM) to identify patients treated with statins prior to stroke and matched untreated patients to limit the Supplemental Methods Propensity score matching. We used propensity score matching (PPM) to identify patients treated with statins prior to stroke and matched untreated patients to limit the potential for

More information

Controversy, the JNC-8 Hypertension Guidelines

Controversy, the JNC-8 Hypertension Guidelines Controversy, the JNC-8 Hypertension Guidelines Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine Acknowledge assistance of Kevin Kun Xiang,

More information

The BEAUTIFUL Study Backgrounder

The BEAUTIFUL Study Backgrounder The BEAUTIFUL Study Backgrounder About the BEAUTIFUL study The BEAUTIFUL (MorBidity-mortality EvAlUaTion of the I f inhibitor Procoralan in patients with coronary disease and left ventricular dysfunction)

More information

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION Hull & East Riding Prescribing Committee PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION For guidance on Primary Prevention please see NICE guidance http://www.nice.org.uk/guidance/cg181

More information

Articles. For personal use. Only reproduce with permission from Elsevier Ltd.

Articles. For personal use. Only reproduce with permission from Elsevier Ltd. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Helen M Colhoun,

More information

Always Start with PECO

Always Start with PECO Goals of This Course Be able to understand a study design (very basic concept) Be able to understand statistical concepts in a medical paper Be able to perform a data analysis Understanding: PECO study

More information

Clinical Practice Guideline for Adult Hypertension - Prevention, Screening, Counseling and Management

Clinical Practice Guideline for Adult Hypertension - Prevention, Screening, Counseling and Management Clinical Practice Guideline for Adult - Prevention, Screening, Counseling and Management is the most common primary diagnosis in America. About 78 million US adults have been diagnosed with high blood

More information

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE

ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.

More information

Rivaroxaban for acute coronary syndromes

Rivaroxaban for acute coronary syndromes Northern Treatment Advisory Group Rivaroxaban for acute coronary syndromes Lead author: Nancy Kane Regional Drug & Therapeutics Centre (Newcastle) May 2014 2014 Summary Current long-term management following

More information

REACH Risk Evaluation to Achieve Cardiovascular Health

REACH Risk Evaluation to Achieve Cardiovascular Health Dyslipidemia and type 1 diabetes mellitus History: A 15-year-old girl is seen in the endocrinology clinic for a routine follow-up visit for type 1 diabetes. She was diagnosed with diabetes at 12 years

More information

Diabetes and cardiovascular risk: MIND.IT Study

Diabetes and cardiovascular risk: MIND.IT Study Diabetes and cardiovascular risk: MIND.IT Study The clinical reality of guidelines for primary prevention of cardiovascular disease in type 2 diabetes in Italy Prof. Ivana Zavaroni Dipartimento di Medicina

More information

Cardiovascular Disease Prevention. Dr Nicole KARAM, MD, MPH Interventional Cardiology European Hospital Georges Pompidou

Cardiovascular Disease Prevention. Dr Nicole KARAM, MD, MPH Interventional Cardiology European Hospital Georges Pompidou Cardiovascular Disease Prevention Dr Nicole KARAM, MD, MPH Interventional Cardiology European Hospital Georges Pompidou Atherosclerotic CVD, especially CHD, remains the leading cause of premature death

More information

PHYSICAL EVALUATION I (Dent 5121) Neurologic System

PHYSICAL EVALUATION I (Dent 5121) Neurologic System PHYSICAL EVALUATION I (Dent 5121) Neurologic System Lecture Objectives After today s lecture, the student will be able to: 1. Identify patients currently suffering from or having a history of cerebrovascular

More information

Lipids: Understanding The New Prevention Guidelines

Lipids: Understanding The New Prevention Guidelines Lipids: Understanding The New Prevention Guidelines What you need to know J. Murray Estess MD Don t shoot the Messenger What has changed compared to ATP3 guideline? Initiate either moderate-intensity or

More information

MANAGEMENT of HYPERTENSION. R. Michael Culpepper, M.D. University of South Alabama

MANAGEMENT of HYPERTENSION. R. Michael Culpepper, M.D. University of South Alabama MANAGEMENT of HYPERTENSION R. Michael Culpepper, M.D. University of South Alabama DISCLOSURE Any Drug or Product Mentioned in this Discussion is Purely Illustrative and not a Commercial Endorsement All

More information

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Home SVCC Area: English - Español - Português Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease Martial G. Bourassa, MD Research Center, Montreal Heart Institute, Montreal, Quebec,

More information

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING

More information

Key priorities for implementation are around the diagnosis of hypertension and the recommended use of Ambulatory Blood Pressure Monitoring (ABPM)

Key priorities for implementation are around the diagnosis of hypertension and the recommended use of Ambulatory Blood Pressure Monitoring (ABPM) Date of issue: December 2011 Written by Sara Wilds & Kathryn Buchanan Prescribing Points A NEWSLETTER FOR ALL HEALTH CARE PROFESSIONALS IN OXFORDSHIRE, WRITTEN BY THE MEDICINES MANAGEMENT TEAM, OXFORDSHIRE

More information

Health Authority Abu Dhabi. Issue Date: July 2009

Health Authority Abu Dhabi. Issue Date: July 2009 Health Authority Abu Dhabi هيئة الصحة - أبوظبي Title: HAAD Standards for diagnosis, management and data reporting for diabetes. Reference: PHP/PHPr/DC/02 Issue Date: July 2009 1. Purpose 1.1 The Health

More information

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Guidelines Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence Stroke/TIA Nearly 700,000 ischemic strokes and 240,000 TIAs every year in the United States Currently, the risk for

More information

Statins patient decision aid

Statins patient decision aid Statins patient decision aid What this decision aid is for This decision aid is intended to assist health professionals in consultations with patients in whom treatment with a statin is being considered,

More information

Kaiser Permanente National Aspirin Recommendations

Kaiser Permanente National Aspirin Recommendations Kaiser Permanente National Aspirin Recommendations Aspirin Therapy* for people without ASCVD (adapted from USPSTF): Initiate aspirin in men age 45-69 years and women age 55-69 years with 15% ASCVD Risk

More information

Article. Heart health and cholesterol levels of Canadians, 2007 to 2009. Component of Statistics Canada Catalogue no. 82-625-X Health Fact Sheets

Article. Heart health and cholesterol levels of Canadians, 2007 to 2009. Component of Statistics Canada Catalogue no. 82-625-X Health Fact Sheets Component of Statistics Canada Catalogue no. 82-625-X Health Fact Sheets Article Heart health and cholesterol levels of Canadians, 2007 to 2009 March How to obtain more information For information about

More information

Running head: QUALITY ASSURANCE PROJECT: MANAGING HYPERTENSION

Running head: QUALITY ASSURANCE PROJECT: MANAGING HYPERTENSION Quality Assurance Project: 1 Running head: QUALITY ASSURANCE PROJECT: MANAGING HYPERTENSION Quality Assurance Project: Managing Hypertension Kendra L. Newland Otterbein College Quality Assurance Project:

More information

The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes

The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes European Heart Journal Supplements (2004) 6 (Supplement G), G3 G7 The interplay of cardiovascular risk factors in the metabolic syndrome and type 2 diabetes D.J. Betteridge* Department of Medicine, University

More information

DAFNE Data Collection: Full Baseline

DAFNE Data Collection: Full Baseline Type of DAFNE course attended? Standard 1 week 5 week Pump Number of course days attended? days (Range: 1 5 days) Please record the method of data collection (more than one can be selected where necessary):

More information

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized

More information

Quantifying Life expectancy in people with Type 2 diabetes

Quantifying Life expectancy in people with Type 2 diabetes School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney The evidence Life expectancy reduced by

More information

IQWiG Reports - Commission No. A Executive Summary

IQWiG Reports - Commission No. A Executive Summary IQWiG Reports - Commission No. A05-07 Benefit assessment of long-term blood glucose lowering to nearnormal levels in patients with type 2 diabetes mellitus 1 Executive Summary 1 Translation of the executive

More information

Explanation for the ACCORD outcomes?

Explanation for the ACCORD outcomes? Explanation for the ACCORD outcomes? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Practical Ways to Achieve Targets in Diabetes Care Keystone, Colorado 18 July 2014 Duality

More information

HYPERTENSION What is blood pressure? What are the risks of high blood pressure? Can high blood pressure be treated?

HYPERTENSION What is blood pressure? What are the risks of high blood pressure? Can high blood pressure be treated? HYPERTENSION What is blood pressure? Blood pressure is the force required to circulate blood throughout the body. As the heart contracts, the pressure within the blood vessels rises to a maximum or top

More information

Both Amiloride and Nebivolol Have a More Favourable Effect on Glucose Tolerance Than Hydrochlorothiazide in the Treatment of Essential Hypertension

Both Amiloride and Nebivolol Have a More Favourable Effect on Glucose Tolerance Than Hydrochlorothiazide in the Treatment of Essential Hypertension Both Amiloride and Nebivolol Have a More Favourable Effect on Glucose Tolerance Than Hydrochlorothiazide in the Treatment of Essential Hypertension Stears AJ, Woods SH, Watts MM, Graggaber J, Burton TJ,

More information

Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과

Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과 Cardiovascular risk calculator for diabetic patients 이해영서울대학병원순환기내과 Contents Need of risk engine for diabetic patients Three main approaches of global cardiovascular risk estimation in diabetes Validation

More information

Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among People at Increased Risk

Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among People at Increased Risk Combined Diet and Physical Activity Promotion s to Prevent Type 2 Diabetes Among People at Increased Risk Results of Comparative Studies of Combined Diet & Physical Activity vs. Categorical Outcomes Author,

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION European Medicines Agency London, 19 July 2007 Doc. Ref. EMEA/CHMP/EWP/311890/2007 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR

More information

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common

More information